<html>
<head>PUBMED IDs for MAGE-D2</head>
<body bgcolor='#C5F0F2'><h1>MAGE-D2</h1><a href='https://pubmed.ncbi.nlm.nih.gov/11313144/'>MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily.</a> April 21  2001<br><a href='https://pubmed.ncbi.nlm.nih.gov/16424981/'>The role of genetic markers--NAP1L1, MAGE-D2, and MTA1--in defining small-intestinal carcinoid neoplasia.</a> January 21  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/16512680/'>Comparative proteomics of pulmonary tumors with neuroendocrine differentiation.</a> March 4  2006<br><a href='https://pubmed.ncbi.nlm.nih.gov/19383316/'>Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas.</a> May 30  2009<br><a href='https://pubmed.ncbi.nlm.nih.gov/22791814/'>The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells.</a> January 19  2012<br></body></html>
